PDCD1 and cancer: While single-agent anti-PD-1 shows limited benefit in most patient cohorts with GBM, combination ICIs target multiple independent steps in the cancer–immunity cycle; when dosed optimally, they improved patient outcomes compared with anti-PD-1 alone in cancers such as melanoma4,32,33.